Mitsui O.S.K. Lines, Ltd. announced that on November 26, it signed a comprehensive memorandum of understanding (MoU) with the Maritime and Port Authority of Singapore (MPA) (Note 1) to deepen cooperation in the fields of decarbonization, digitalisation, and human resources development. MOL and MPA have been cooperating in various initiatives to decarbonize the maritime industry, the new agreement will further promote these initiatives in a wide range of fields. MPA Chief Executive Teo Eng Dih said: “This MoU reaffirms MPA and MOL’s longstanding collaboration. As a maritime hub port, supported by our innovation and research ecosystem, MPA is working closely with industry and tripartite partners to support digitalisation, cybersecurity, decarbonisation and manpower capabilities. We look forward to MOL’s expansion of activities, tapping on both our experience and expertise, to develop scalable solutions for the Singapore-Japan Green and Digital Shipping Corridor and the wider maritime community.” MOL President & CEO Takeshi Hashimoto commented: “We have been focusing on the fields of decarbonization, digitalisation, and human resources development, which we have decided to deepen cooperation with MPA this time. MPA is committed to working hard to create a sustainable maritime industry in Singapore, the hub of the maritime industry. We pay our respect to MPA for its enthusiasm and energy. The fields of bilateral cooperation are also a challenge for the maritime industry as a whole, and I hope we can increase the feasibility by working together as like-minded people. We are confident that the establishment of this comprehensive cooperative relationship will contribute to the maritime industry in general.” Left: MPA Chief Executive Teo Eng Dih Right: MOL President & CEO Takeshi Hashimoto Specifically, the scope of the MoU covers the following: 1 Collaboration in the field of decarbonization in the maritime industry in general. Mutual collaboration to establish a supply system for next-generation fuel sources such as methanol, ammonia, and hydrogen. The collaboration will also include study on the use of wind technology. 2 Digitalization and maritime innovation. Improving voyage management and efficiency of transport operations through digitalization, including development of cybersecurity, collaboration on autonomous vessel trials, and nurturing marine innovation ecosystem that emphasizes collaboration with local startups. 3 Joint development of maritime human resources. Grow and enhance manpower capabilities, including grooming seafarers and shore-based workforce. MOL will continue its group-wide concerted effort, in close cooperation with MPA and other major maritime sectors, to achieve sustainable GHG net-zero emissions and contribute to the realization of a decarbonized society. ・MOL participates in the Green & Digital Shipping Corridors (GDSC) The MPA is building strong partnerships with national port stakeholders to accelerate decarbonization in the maritime industry, with the goal of promoting the development and broad adoption of next-generation fuels and technologies. MOL joined this MPA-led corridor and participated in discussions among major maritime organizations in both public and private sectors and across borders. ・MOL participates in the Maritime Energy Training Facility (METF) In September 2024, MOL joined MPA’s initiative to promote training for seafarers involved in next-generation fuel transport. This aims to provide a new facility that will offer more seafarers with training to handle next-generation fuels such as ammonia, which reduces carbon emissions. Source: Maritime and Port Authority of SingaporeCouple charged in ring suspected of stealing $1 million in Lululemon clothes
It's Dana Holgorsen's 'focus on execution' that's impressing Matt Rhule — not just his play callsThe new, 12-team College Football Playoff brings with it a promise to be bigger, more exciting, more lucrative. Perfect or 100% fair? Well, nobody ever believed that. The first expanded playoff bracket unveiled Sunday left a presumably deserving Alabama team on the sideline in favor of an SMU squad that finished with a better record after playing a schedule that was not as difficult. It ranked undefeated Oregon first but set up a possible rematch against Ohio State, the team that came closest to beating the Ducks this year. It treated underdog Boise State like a favorite and banged-up Georgia like a world beater at No. 2. It gave Ohio State home-field advantage against Tennessee for reasons it would take a supercomputer to figure out. It gave the sport the multiweek tournament it has longed for, but also ensured there will be plenty to grouse about between now and when the trophy is handed out on Jan. 20 after what will easily be the longest college football season in history. All of it, thankfully, will be sorted out on the field starting with first-round games on campuses Dec. 20 and 21, then over three succeeding rounds that will wind their way through traditional bowl sites. Maybe Oregon coach Dan Lanning, whose undefeated Ducks are the favorite to win it all, put it best when he offered: "Winning a national championship is not supposed to be easy.” Neither, it turns out, is figuring out who should play for it. The Big Ten will lead the way with four teams in the tournament, followed by the SEC with three and the ACC with two. The lasting memory from the inaugural bracket will involve the decision that handed the ACC that second bid. Alabama of the SEC didn't play Saturday. SMU of the ACC did. The Mustangs fell behind by three touchdowns to Clemson before coming back to tie. But they ultimately lost 34-31 on a 56-yard field goal as time expired. “We were on pins and needles,” SMU coach Rhett Lashley said. “Until we saw the name ‘SMU’ up there, we were hanging on the edge. We're really, really happy and thankful to the committee for rewarding our guys for their total body of work." The Mustangs only had two losses, compared to three for the Crimson Tide. Even though SMU's schedule wasn't nearly as tough, the committee was impressed by the way the Mustangs came back against Clemson. “We just felt, in this particular case, SMU had the nod above Alabama,” said Michigan athletic director Warde Manuel, the chairman of the selection committee. “But it’s no disrespect to Alabama’s strength of schedule. We looked at the entire body of work for both teams.” Alabama athletic director Greg Byrne was gracious, up to a point. “Disappointed with the outcome and felt we were one of the 12 best teams in the country,” he said on social media. He acknowledged — despite all of Alabama’s losses coming against conference opponents this season — that the Tide’s push to schedule more games against teams from other major conferences in order to improve its strength of schedule did not pay off this time. “That is not good for college football," Byrne said. Georgia, the SEC champion, was seeded second; Boise State, the Mountain West champion, earned the third seed; and Big 12 titlist Arizona State got the fourth seed and the fourth and final first-round bye. All will play in quarterfinals at bowl games on Dec. 31-Jan. 1. Clemson stole a bid and the 12th seed with its crazy win over SMU, the result that ultimately cost Alabama a spot in the field. The Tigers moved to No. 16 in the rankings, but got in as the fifth-best conference winner. The conference commissioners' idea to give conference champions preferable treatment in this first iteration of the 12-team playoff could be up for reconsideration after this season. The committee actually ranked Boise State, the Mountain West Champion, at No. 9 and Big 12 champion Arizona State at No. 12, but both get to skip the first round. Another CFP guideline: There’s no reseeding of teams after each round, which means no break for Oregon. The top-seeded Ducks will face the winner of Tennessee-Ohio State in the Rose Bowl. Oregon beat Ohio State 32-31 earlier this year in one of the season’s best games. No. 12 Clemson at No. 5 Texas, Dec. 21. Clemson is riding high after the SMU upset, while Texas is 0-2 against Georgia and 11-0 vs. everyone else this season. The winner faces ... Arizona State in the Peach Bowl. Huh? No. 11 SMU at No. 6 Penn State, Dec. 21. The biggest knock against the Mustangs was that they didn't play any big boys with that 60th-ranked strength of schedule. Well, now they get to. The winner faces ... Boise State in the Fiesta Bowl. Yes, SMU vs. Boise was the quarterfinal we all expected. No. 10 Indiana at No. 7 Notre Dame, Dec. 20. Hoosiers coach Curt Cignetti thought his team deserved a home game. Well, not quite but close. The winner faces ... Georgia in the Sugar Bowl. The Bulldogs got the No. 2 seed despite a throwing-arm injury to QB Carson Beck. But what else was the committee supposed to do? No. 9 Tennessee at No. 8 Ohio State , Dec. 21. The Buckeyes (losses to Oregon, Michigan) got home field over the Volunteers (losses to Arkansas, Georgia) in a matchup of programs with two of the biggest stadiums in football. The winner faces ... Oregon in the Rose Bowl. Feels like that matchup should come in the semifinals or later. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Dec 8, 2024-- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from a five-year follow-up of the pivotal Phase III POLARIX study evaluating Polivy ® (polatuzumab vedotin-piiq) in combination with Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) in people with untreated diffuse large B-cell lymphoma (DLBCL). Data were presented in an oral session at the 66th American Society of Hematology (ASH) Annual Meeting and Exposition, December 7-10, 2024 in San Diego, California. This latest analysis conducted after a median follow-up of 60.9 months, includes descriptive data on primary and secondary endpoints, as well as safety results. “POLARIX was the first trial to elevate treatment standards for frontline diffuse large B-cell lymphoma in 20 years and we are additionally encouraged by the five-year follow-up results,” said Levi Garraway, M.D., Ph.D., Genentech’s chief medical officer and head of Global Product Development. “More than 38,000 people worldwide have been treated with Polivy in combination with R-CHP and these data continue to underscore its potential to improve outcomes for people diagnosed with this aggressive lymphoma.” Follow-up exploratory analysis after five-years indicated a positive trend in overall survival (OS) in the intent-to-treat (ITT) population in favor of Polivy in combination with R-CHP compared to Rituxan plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP). Results showed a trend in reduction in the risk of death (HR 0.85; 95% CI: 0.63–1.15) for people with previously untreated DLBCL with the Polivy combination, an improvement on the three-year follow-up data (HR 0.94; 95% CI: 0.67–1.33). The five-year analysis of POLARIX indicates that the full difference in OS between treatment arms has yet to be observed and an additional two years of follow-up will continue. “Diffuse large B-cell lymphoma is a notoriously challenging cancer to treat, however, Polivy in combination with R-CHP has shown to be a critical advance for patients by helping to reduce relapse and disease progression,” said Gilles Salles, M.D., Ph.D., chief of Lymphoma Service, Division of Hematological Malignancies, Memorial Sloan Kettering Cancer Center, New York. “The survival trend seen in this follow-up analysis reinforces the potential impact of frontline treatment with Polivy in combination with R-CHP and its role as a standard of care therapy.” In addition to the positive trend in OS, an observational analysis suggested nearly 25% fewer follow-up treatments such as radiation, systemic chemotherapy and CAR-T cell therapy were needed in patients receiving Polivy in combination with R-CHP compared to those treated with R-CHOP (38.3% versus 61.7%). At five years of follow-up, benefits in progression-free survival and disease-free survival with Polivy in combination with R-CHP were maintained, consistent with the three-year follow-up data, reinforcing the potential of Polivy in combination with R-CHP to provide durable and lasting remissions. The latest follow-up data also showed a numerical reduction in death related to patients’ lymphoma in those treated with Polivy in combination with R-CHP compared to those treated with R-CHOP (9.0% versus 11.4%). The safety profile remains consistent with the known profiles of the individual study medicines with no new safety signals observed, reinforcing the positive benefit-risk profile of this Polivy combination. Results from an expanded cohort of 1,000 patients including global and Chinese patients demonstrated comparability to the global ITT population. Polivy in combination with R-CHP is currently approved for the treatment of first-line (1L) DLBCL in more than 90 countries worldwide including the U.S., countries throughout the EU, the U.K., Japan, Canada and China. Genentech continues to work with health authorities around the world to bring this treatment regimen to even more patients. Genentech aims to offer various treatment options for DLBCL that meet the diverse needs of patients and healthcare systems. In an effort to elevate treatment standards even further, Genentech is exploring Polivy in combination with other molecules, including its bispecific antibodies. Studies include the Phase III SUNMO trial evaluating the efficacy and safety of subcutaneously administered Lunsumio ® (mosunetuzumab-axgb) in combination with intravenous (IV) Polivy versus IV Rituxan plus gemcitabine and oxaliplatin (R-GemOx) in second-line or later DLBCL, and the Phase III SKYGLO trial investigating the efficacy of Polivy in combination with R-CHP and Columvi ® (glofitamab-gxbm) versus Polivy in combination with R-CHP in 1L DLBCL. About the POLARIX Study POLARIX [ NCT03274492 ] is an international Phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy, safety and pharmacokinetics of Polivy ® (polatuzumab vedotin-piiq) plus Rituxan ® (rituximab), cyclophosphamide, doxorubicin and prednisone (R-CHP) versus Rituxan, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) in people with previously untreated diffuse large B-cell lymphoma (DLBCL). Eight-hundred and seventy-nine patients were randomized 1:1 to receive either Polivy plus R-CHP plus a vincristine placebo for six cycles, followed by Rituxan for two cycles; or R-CHOP plus a Polivy placebo for six cycles, followed by two cycles of Rituxan. The primary outcome measure is progression-free survival as assessed by the investigator using the Lugano Response Criteria for malignant lymphoma. POLARIX is being conducted in collaboration with The Lymphoma Study Association (LYSA) and The Lymphoma Academic Research Organisation (LYSARC). About Diffuse Large B-Cell Lymphoma Diffuse large B-cell lymphoma (DLBCL) is an aggressive (fast-growing) blood cancer and is the most common form of non-Hodgkin’s lymphoma (NHL) in the U.S. While many people with DLBCL are responsive to treatment, the majority of those who relapse or are refractory to subsequent treatments have poor outcomes. DLBCL not otherwise specified is the most common category of large B-cell lymphoma (LBCL) and accounts for about 80% or more of cases. It applies to cases that do not fall into any specific disease subgroups of LBCL. About Polivy ® (polatuzumab vedotin-piiq) Polivy is a first-in-class anti-CD79b antibody-drug conjugate (ADC). The CD79b protein is expressed specifically in the majority of B cells, an immune cell impacted in some types of non-Hodgkin’s lymphoma (NHL), making it a promising target for the development of new therapies. Polivy binds to cancer cells such as CD79b and destroys these B cells through the delivery of an anti-cancer agent, which is thought to minimize the effects on normal cells. Polivy is being developed by Genentech using Pfizer ADC technology and is currently being investigated for the treatment of several types of NHL. Polivy U.S. Indication Polivy is a prescription medicine used with other medicines (a rituximab product, cyclophosphamide, doxorubicin, and prednisone) as a first treatment for adults who have moderate to high risk diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS) or high-grade B-cell lymphoma (HGBL). Polivy is a prescription medicine used with other medicines, bendamustine and a rituximab product, to treat DLBCL in adults who have progressed after at least 2 prior therapies. Important Safety Information Possible serious side effects Everyone reacts differently to Polivy therapy, so it’s important to know what the side effects are. Some people who have been treated with Polivy have experienced serious to fatal side effects. Your doctor may stop or adjust your treatment if any serious side effects occur. Be sure to contact your healthcare team if there are any signs of these side effects. Side effects seen most often The most common side effects during treatment were Polivy may lower your red or white blood cell counts and increase uric acid levels. Polivy may not be for everyone. Talk to your doctor if you are These may not be all the side effects. Talk to your healthcare provider for more information about the benefits and risks of Polivy treatment. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see the full Prescribing Information and visit https://www.Polivy.com for additional Important Safety Information. About Lunsumio ® (mosunetuzumab-axgb) Lunsumio is a first-in-class CD20xCD3 T-cell engaging bispecific antibody designed to target CD20 on the surface of B cells and CD3 on the surface of T cells. This dual targeting activates and redirects a patient’s existing T cells to engage and eliminate target B cells by releasing cytotoxic proteins into the B cells. A robust clinical development program for Lunsumio is ongoing, investigating the molecule as a monotherapy and in combination with other medicines, for the treatment of people with B-cell non-Hodgkin’s lymphomas, including follicular lymphoma and diffuse large B-cell lymphoma, and other blood cancers. Lunsumio U.S. Indication Lunsumio (mosunetuzumab-axgb) is a prescription medicine used to treat adults with follicular lymphoma whose cancer has come back or did not respond to previous treatment, and who have already received two or more treatments for their cancer. It is not known if Lunsumio is safe and effective in children. The conditional approval of Lunsumio is based on response rate. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Lunsumio? Lunsumio may cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Lunsumio and can also be severe or life-threatening. Get medical help right away if you develop any signs or symptoms of CRS at any time, including: Due to the risk of CRS, you will receive Lunsumio on a “step-up dosing schedule.” Your healthcare provider will check you for CRS during treatment with Lunsumio and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Lunsumio, if you have severe side effects. What are the possible side effects of Lunsumio? Lunsumio may cause serious side effects, including: Your healthcare provider may temporarily stop or permanently stop treatment with Lunsumio if you develop severe side effects. The most common side effects of Lunsumio include: tiredness, rash, fever, and headache. The most common severe abnormal blood test results with Lunsumio include: decreased phosphate, increased glucose, and increased uric acid levels. Before receiving Lunsumio, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Lunsumio? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, tremors, sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of CRS or neurologic problems. These are not all the possible side effects of Lunsumio. Talk to your healthcare provider for more information about the benefits and risks of Lunsumio. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects, as well as the Lunsumio full Prescribing Information and Medication Guide or visit https://www.Lunsumio.com . About Columvi ® (glofitamab-gxbm) Columvi is a CD20xCD3 T-cell engaging bispecific antibody designed to target CD3 on the surface of T cells and CD20 on the surface of B cells. Columvi was designed with a novel 2:1 structural format. This T-cell engaging bispecific antibody is engineered to have one region that binds to CD3, a protein on T cells, a type of immune cell, and two regions that bind to CD20, a protein on B cells, which can be healthy or malignant. This dual-targeting brings the T cell in close proximity to the B cell, activating the release of cancer cell-killing proteins from the T cell. Columvi is part of Genentech’s broad and industry-leading CD20xCD3 T-cell-engaging bispecific antibody clinical development program that also includes Lunsumio ® (mosunetuzumab), which aims to provide tailored treatment options that suit the diverse needs, preferences, and experiences of people with blood cancers and healthcare systems. Genentech is investigating Columvi as a monotherapy and in combination with other medicines for the treatment of diffuse large B-cell lymphoma and mantle cell lymphoma. Columvi U.S. Indication Columvi (glofitamab-gxbm) is a prescription medicine to treat adults with certain types of diffuse large B-cell lymphoma (DLBCL) or large B-cell lymphoma (LBCL) that has come back (relapsed) or that did not respond to previous treatment (refractory), and who have received 2 or more prior treatments for their cancer. It is not known if Columvi is safe and effective in children. The conditional approval of Columvi is based on response rate and durability of response. There are ongoing studies to establish how well the drug works. What is the most important information I should know about Columvi? Columvi can cause Cytokine Release Syndrome (CRS), a serious side effect that is common during treatment with Columvi, and can also be serious and lead to death. Call your healthcare provider or get emergency medical help right away if you develop any signs or symptoms of CRS, including: Due to the risk of CRS, you will receive Columvi on a “step-up dosing schedule”. Your healthcare provider will monitor you for CRS during treatment with Columvi and may treat you in a hospital if you develop signs and symptoms of CRS. Your healthcare provider may temporarily stop or completely stop your treatment with Columvi if you have severe side effects. Carry the Columvi Patient Wallet Card with you at all times and show it to all of your healthcare providers. The Columvi Patient Wallet Card lists the signs and symptoms of CRS you should get emergency medical help for right away. What are the possible side effects of Columvi? Columvi may cause serious side effects, including: The most common side effects of Columvi include: CRS, muscle and bone pain, rash, and tiredness. The most common severe abnormal lab test results with Columvi include: decreased white blood cells, decreased phosphate (an electrolyte), increased uric acid levels, and decreased fibrinogen (a protein that helps with blood clotting). Your healthcare provider may temporarily stop or completely stop treatment with Columvi if you develop certain side effects. Before receiving Columvi, tell your healthcare provider about all of your medical conditions, including if you: Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. What should I avoid while receiving Columvi? Do not drive, operate heavy machinery, or do other dangerous activities if you develop dizziness, confusion, shaking (tremors), sleepiness, or any other symptoms that impair consciousness until your signs and symptoms go away. These may be signs and symptoms of neurologic problems. These are not all the possible side effects of Columvi. Talk to your health care provider for more information about the benefits and risks of Columvi. You may report side effects to the FDA at (800) FDA-1088 or http://www.fda.gov/medwatch . You may also report side effects to Genentech at (888) 835-2555. Please see Important Safety Information, including Serious Side Effects , as well as the Columvi full Prescribing Information and Medication Guide or visit https://www.Columvi.com About Genentech in Hematology For more than 20 years, Genentech has been developing medicines with the goal to redefine treatment in hematology. Today, we’re investing more than ever in our effort to bring innovative treatment options to people with diseases of the blood. For more information visit http://www.gene.com/hematology . About Genentech Founded more than 40 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious and life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com . Dr. Salles has financial interests related to Roche and Genentech. View source version on businesswire.com : https://www.businesswire.com/news/home/20241208818007/en/ CONTACT: Media Contact: Kristen Ingram, (650) 467-6800Advocacy Contact: Catherine Creme Henry, (202) 258-8228Investor Contacts: Loren Kalm, (650) 225-3217 Bruno Eschli, 011 41 61 687 5284 KEYWORD: CALIFORNIA UNITED STATES NORTH AMERICA INDUSTRY KEYWORD: BIOTECHNOLOGY HEALTH PHARMACEUTICAL CLINICAL TRIALS ONCOLOGY SOURCE: Genentech Copyright Business Wire 2024. PUB: 12/08/2024 12:30 PM/DISC: 12/08/2024 12:30 PM http://www.businesswire.com/news/home/20241208818007/en
I’m a Celeb’s Maura Higgins' relationships, celebrity friends, and career to dateThe global economy is navigating uncharted waters. Geopolitical conflicts, supply chain disruptions and political uncertainties dominate headlines, casting a shadow over economic growth and stability. As policy-makers worldwide grapple with these challenges, a Donald Trump has re-entered the global stage as US president-elect. However, it would be short sighted to believe that the geopolitical landscape is being shaped by one leader. Across continents, governments are responding to their electorates’ concerns by embracing strategies like friendshoring and nearshoring. While these approaches address local anxieties about globalization, they also raise the spectre of trade wars, an often-ineffective solution to deeply rooted challenges. Local anxiety driving global decisions Globalization, once seen as a driver of prosperity, is increasingly viewed with suspicion by many, with electorates becoming more vocal about job security, fair trade and national sovereignty. These concerns have prompted leaders to pivot towards more domestically-oriented economic strategies. Policies encouraging companies to move production closer to home or to allied nations reflect this shift. While such moves may alleviate voter concerns in the short term, they often come at a high cost. The International Monetary Fund (IMF) estimates that increasing trade restrictions could reduce global economic output by a staggering $7.4 trillion. The stakes are too high to let reactionary policies undermine long-term global growth. Trade wars: A misguided solution Trump’s imminent return to the White House now brings renewed attention to the topics of tariffs and trade wars as policy tools. Trump’s rhetoric on tariffs as a panacea for economic disparities resonates with segments of the electorate, but risks igniting economic conflicts that hurt all parties involved. During his first term as president, the US-China trade war disrupted supply chains, raised costs for businesses and imposed billions of dollars in economic damage on both sides. US farmers alone faced estimated losses exceeding $12 billion annually, prompting federal subsidies to offset the impact. Meanwhile, tariffs on Chinese goods drove up production costs for US manufacturers and consumer prices. The US Federal Reserve estimated the trade war reduced US GDP by 0.3% – equivalent to $62 billion – while global supply chain networks struggled to adapt, leading to higher prices and market volatility. Trump’s proposed trade policies for his second term, including broad tariffs on imports, could amplify these effects. While intended to protect US industries, such measures risk increasing inflation and hurting consumer spending power. The broader economic implications include heightened tensions with trade partners and potential retaliatory measures, exacerbating further global economic fragmentation. The question we face is this: Can we establish stronger frameworks to promote stability and sustainable growth in an era of rising protectionism? The answer lies in balance. We must heed the electorate’s concerns without dismantling the systems that underpin global prosperity. If we fail to address these issues, the consequences will be severe. Rising trade barriers and economic fragmentation could lead to a prolonged global recession. The IMF warns that reduced trade opportunities could hinder productivity, suppress wages and stifle technological advancement. For emerging economies, the impacts would be particularly devastating. Reduced trade opportunities could undermine industrialization efforts, exacerbate inequality and slow poverty reduction. Many developing nations rely heavily on export-led growth; disruptions to global supply chains would compromise their access to critical markets, increasing unemployment and social unrest. The broader implications are geopolitical as well as economic. Fragmented trade relationships risk deepening divides between nations, fostering mistrust and competition. In an interconnected world, such outcomes threaten the collective ability to address global challenges like climate change and energy transitions. To chart a sustainable path forward, we must embrace policies that strike a balance between local and global interests. Friendshoring and nearshoring can coexist with global cooperation if implemented thoughtfully. The goal should not be to isolate but to adapt – reshaping globalization to meet the needs of today’s interconnected world. Policy-makers must resist the allure of quick fixes. Instead, they should pursue policies that promote inclusivity, resilience and innovation. The global economy’s momentum can only be maintained through collaboration and shared responsibility. The current landscape is fraught with challenges, but it is also an opportunity to redefine the rules of engagement in the global economy. By addressing the root causes of voter anxieties and fostering international cooperation, we can build a more resilient and equitable system. As we navigate this era of uncertainty, let us remember that long-term growth is the ultimate prize. To secure it, we must better understand and navigate the interconnected nature of global shocks, electorate concerns and the need for cooperation. The path forward is complex, but with pragmatic leadership and a commitment to shared prosperity, it is within reach. Source: World Economic Forum
What we can VERIFY about Trump’s plan to use the military to support mass deportationsUnique among ‘Person of the Year’ designees, Donald Trump gets a fact-check from Time magazine
None
A claim is doing rounds on social media that far-right streamer Nick Fuentes had allegedly set his house on fire. Fuentes had been the center of attention since the election of Donald Trump as the next US president after he made a controversial comment taunting abortion rights activists. As part of the backlash from the comment, Fuentes' address in Berwyn, Illinois was made public on social media and women started visiting the address to confront Fuentes. Amid that, a claim surfaced that the 26-year-old set his house on fire to escape the wrath of the women visiting Fuentes' house. However, Times Now Digital can confirm that Nick Fuentes never really set his house on fire. He had said in a stream in reaction to the backlash that he would set his house on fire. Since then, the rumour has been doing rounds on social media that Fuentes had set his house in Illinois on fire. What Caused The Backlash? After Donald Trump was confirmed as the President-elect on the evening of the election day on November 5, Fuentes mocked the abortion rights activist by posting on X, "Your body, my choice. Forever." It was a dig at the popular abortion rights slogan, "my body, my choice." The comment followed a massive backlash on and beyond social media. After Fuentes' address was shared on social media, women visited the far-right activists' house to confront him. Nick Fuentes Booked For Battery One of the women to visit Nick Fuentes' home was Marla Rose. After Fuentes was confronted by the woman, he pepper sprayed her and then seized her phone. In a video recorded by the woman, Fuentes can be seen seizing her phone and stomping it on the ground. The video ends at that point. After Marla Rose pressed charges against Fuentes, the Berwyn Police Department booked Fuentes on November 24 and was later released. He is set to appear in court for his first trial on December 9. Get Latest News Live on Times Now along with Breaking News and Top Headlines from US Buzz, World and around the world.
The supply chain management firm Blue Yonder has confirmed a ransomware attack. The scale of the incident has disrupted its services, and the impact has affected many customers. The logistics company has more than 3,000 clients around the world. According to Blue Yonder, the firm says it has “experienced disruptions to its managed services hosted environment”. Subsequent investigation confirmed that it was a ransomware attack.” This continues: “Since learning of the incident, the Blue Yonder team has been working diligently together with external cybersecurity firms to make progress in their recovery process. We have implemented several defensive and forensic protocols,” the announcement reads. “With respect to the Blue Yonder Azure public cloud environment, we are actively monitoring and currently do not see any suspicious activity.” Following the news of the ransomware attack on Blue Yonder, Digital Journal heard from Steve Cobb, CISO at SecurityScorecard . Cobb begins by laying out the background of the incident and the residual impact: “Blue Yonder, a supply chain software provider serving U.S. and U.K. grocery chains, was hit by a ransomware attack. The attack significantly impacted two of the four largest grocery chains in the U.K., causing operational disruptions and forcing these retailers to revert to backup processes. In the U.S., prominent chains, including Kroger and Albertsons, rely on Blue Yonder, underscoring the potential widespread implications of this incident.” Next Cobb considers why retail is often in the sights of cyber-criminals: “The supplier ecosystem is a highly desirable target for ransomware groups. Third-party breach victims are often not aware of an incident until they receive a ransomware note, allowing time for attackers to infiltrate numerous companies without being detected. These organizations house vast amounts of sensitive data, making them prime targets for threat actors and amplifying the attack surface of a single breach.” Cobb also assesses the targets of the attack: “These supply chain attacks typically focus on data security and privacy concerns”. In terms of what retailers can do to try and prevent future attacks of this nature, Cobb recommends: “Organizations should approach these incidents with a broader focus on cyber resiliency, considering how these attacks impact their ability to serve customers and recover business operations. Organizations must consider this a wake-up call to enhance proactive security measures, including their third-party providers.” In addition, Cobb puts forward: “A robust approach includes continuous monitoring and comprehensive visibility across supply chain risk. By implementing these processes, organizations can navigate their supply chain cybersecurity and better equip themselves for attacks.” Dr. Tim Sandle is Digital Journal's Editor-at-Large for science news.Tim specializes in science, technology, environmental, business, and health journalism. He is additionally a practising microbiologist; and an author. He is also interested in history, politics and current affairs.S&W Files First Quarter 2025 10-Q
The Senior Special Assistant on Public Communications and New Media to the Federal Capital Territory (FCT) Minister, Lere Olayinka, has challenged social media activists alleging land grabbing against the Minister to show evidence. Olayinka noted that the people have been using cyberspace to peddle falsehoods against the Minister. He said that the amount of time the critics committed to their trade in stocks would have been enough to do proper investigations to come up with evidence on the matters they were making baseless allegations. The Aide said, “Referring to a recent video being circulated on land located Life Camp, particularly Plot No. 2241, Gwarimpa District, Cadastral Zone C02, Abuja, the FCT Minister’s Spokesperson challenged those claiming ownership of the land to provide Right of Occupancy or Certificate of Occupancy granted by the FCTA. “A construction company, Paulosa Nigeria Limited occupied the land as a temporary office, under a Temporary Right of Occupancy arrangement granted in 1984 (40 years ago). “For 36 years, the company occupied the land, built permanent structures on it and rented them out without any approval from the government. “On November 18, 2020, after occupying the land for 36 years without approval, Paulosa Nigeria Limited applied to the then Minister of the Federal Capital Territory, for the conversion of the Temporary Right of Occupancy to a Statutory Right of Occupancy. “On February 1, 2023, approval was granted to Paulosa Nigeria Limited for a Statutory Right of Occupancy, subject to certain terms and conditions. “Some of the terms and conditions are; payment of Ground Rent Per Square Meter Per Annum, which was N50K/m2 from 2022 to 2023, amounting to N2,332,143; payment of Premium of N500/m2, amounting to N11,660,715 and payment of Ground Rent from 1984 to 2021 (37 years), amounting to N43,144,645. “However, for 20 months, Paulosa Nigeria Limited refused to comply with the terms and conditions for the approval. “Consequent upon the failure of Paulosa Nigeria Limited to comply with the terms and conditions for approval granted for a Right of Occupancy on the said land, the approval was revoked on October 10, 2024, more than 20 months after it was given. “From the above, it should be clear that Paulosa Nigeria Limited never at any time, owned the land. “For instance, if a student who was offered admission to a university, refused to pay the fees stipulated in the offer of admission, and fulfil other terms and conditions for the admission, can the student have any claim to the studentship of the university?”